A case of ovarian carcinosarcoma with germline BRCA2 pathogenic variant

Ovarian carcinosarcoma in hereditary breast and ovarian cancer syndrome is rare. A 43‐year‐old woman with a family history of prostate and uterine or ovarian cancer had an 8‐cm mass in the right ovary. Although computed tomography suggested peritoneal dissemination to the Douglas pouch, she wanted t...

Full description

Saved in:
Bibliographic Details
Published in:The journal of obstetrics and gynaecology research 2024-12, Vol.50 (12), p.2362-2366
Main Authors: Yoriki, Kaori, Izumi, Yuko, Tarumi, Yosuke, Okimura, Hiroyuki, Maeda, Eiko, Mori, Taisuke
Format: Article
Language:English
Subjects:
Adult
BRCA
BRCA2 protein
BRCA2 Protein - genetics
Breast
Breast cancer
Breast carcinoma
Carcinosarcoma - diagnosis
Carcinosarcoma - genetics
Carcinosarcoma - pathology
Chemotherapy
Computed tomography
Female
Fertility
Germ-Line Mutation
germline pathogenic variant
hereditary breast and ovarian cancer syndrome (HBOC)
Humans
Ovarian cancer
Ovarian carcinoma
ovarian carcinosarcoma
Ovarian Neoplasms - diagnosis
Ovarian Neoplasms - genetics
Ovarian Neoplasms - pathology
Ovariectomy
poly(adenosine diphosphate‐ribose) polymerase (PARP) inhibitor
Poly(ADP-ribose) polymerase
Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use
Prostate cancer
Uterine cancer
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ovarian carcinosarcoma in hereditary breast and ovarian cancer syndrome is rare. A 43‐year‐old woman with a family history of prostate and uterine or ovarian cancer had an 8‐cm mass in the right ovary. Although computed tomography suggested peritoneal dissemination to the Douglas pouch, she wanted to preserve her fertility; therefore, she underwent a right salpingo‐oophorectomy. Histopathological diagnosis was carcinosarcoma consisting of high‐grade serous carcinoma and sarcomatous components, including cartilage. Three weeks later, she underwent radical surgery. The disease was classified as advanced stage IIIB (FIGO 2014). A germline BRCA2 pathogenic variant was identified. After postoperative adjuvant chemotherapy, maintenance therapy with a poly(adenosine diphosphate‐ribose) polymerase (PARP) inhibitor was continued for 25 months without recurrence. A detailed examination of a mass in her left breast at her first visit revealed a ductal carcinoma in situ. PARP inhibitors may be effective as maintenance therapy for advanced ovarian carcinosarcoma with germline BRCA mutations.
ISSN:1341-8076
1447-0756
1447-0756
DOI:10.1111/jog.16134